A Phase I, Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Alpelisib (Primary) ; Elgemtumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 16 Sep 2019 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
- 16 Sep 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2020.
- 11 Jul 2018 Planned number of patients changed from 48 to 23.